Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC1118 + paclitaxel
- Development stage
- Unknown
- Lead developer
- GC Biopharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
GC1118 + paclitaxel is a combination therapy comprising GC1118, a novel fully human IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and paclitaxel, a microtubule-stabilizing taxane. GC1118 is designed to bind to a distinct epitope on EGFR compared to cetuximab or panitumumab, allowing it to maintain potent inhibitory activity even in environments with high concentrations of endogenous EGFR ligands. This combination is specifically being evaluated as a second-line treatment for patients with metastatic gastric or gastroesophageal junction adenocarcinoma that harbors EGFR amplification. By combining targeted EGFR blockade with the cytotoxic effects of paclitaxel, the regimen aims to overcome resistance and improve outcomes in this molecularly defined patient population.
- Other names
- anti-EGFR antibody + paclitaxel
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on GC1118 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC1118 + paclitaxel.